Abstract
Cushing disease is most frequently caused by pituitary adenomas that secrete adrenocorticotrophic hormone. Transsphenoidal surgery is the treatment of choice in patients with these tumors because of reported remission rates of 69–93%. More challenging for neurosurgeons and endocrinologists, however, is management of the remaining patients whose Cushing disease is refractory to initial transsphenoidal surgery or recurs after initial remission. Here, we review the treatment options and latest surgical, medical, and radiosurgical advances for patients who have persistent or recurrent Cushing disease after transsphenoidal surgery.
Key Points
-
Repeat transsphenoidal surgery is a safe and effective treatment for recurrent and refractory Cushing disease
-
Radiosurgery carries a notable risk of hypopituitarism and takes longer to achieve remission than transsphenoidal surgery but can be considered for Cushing disease for which multiple surgeries have been unsuccessful or that is caused by adenoma in the cavernous sinus
-
Medical therapy that lowers serum cortisol concentrations can be effective in Cushing disease patients in whom remission cannot be achieved with surgery or radiosurgery, and who, therefore, require lifelong treatment; ketoconazole is the most frequently prescribed therapy but mifepristone is currently being studied
-
Adrenalectomy, particularly in the less invasive laparoscopic form, can provide rapid control of refractory hypercortisolemia, but requires MRI surveillance to monitor for adenoma growth before Nelson syndrome develops
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cushing H (1932) The basophil adenomas of the pituitary body and their clinical manifestation. Bull Johns Hopkins Hosp 50: 137–195
Lindholm J et al. (2001) Incidence and late prognosis of cushing's syndrome: a population-based study. J Clin Endocrinol Metab 86: 117–123
Dekkers OM et al. (2007) Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92: 976–981
Mampalam TJ et al. (1988) Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. Ann Intern Med 109: 487–493
Pouratian N et al. (2007) Outcomes and management of patients with cushing's disease without pathological confirmation of tumor resection after transsphenoidal surgery. J Clin Endocrinol Metab 92: 3383–3388
Rudnik A et al. (2007) Endoscopic transsphenoidal treatment of hormonally active pituitary adenomas. Neuro Endocrinol Lett 28: 438–444
Sonino N et al. (1996) Risk factors and long-term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab 81: 2647–2652
Patil CG et al. (2008) Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. J Clin Endocrinol Metab 93: 358–362
Aghi M et al.: Management of recurrent and refractory Cushing's disease with reoperation and/or proton beam radiosurgery. Clin. Neurosurg, in press
Atkinson AB et al. (2005) Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 63: 549–559
Chee GH et al. (2001) Transsphenoidal pituitary surgery in Cushing's disease: can we predict outcome? Clin Endocrinol (Oxf) 54: 617–626
Chen JC et al. (2003) Transsphenoidal microsurgical treatment of Cushing disease: postoperative assessment of surgical efficacy by application of an overnight low-dose dexamethasone suppression test. J Neurosurg 98: 967–973
Esposito F et al. (2006) Clinical review: early morning cortisol levels as a predictor of remission after transsphenoidal surgery for Cushing's disease. J Clin Endocrinol Metab 91: 7–13
Hammer GD et al. (2004) Transsphenoidal microsurgery for Cushing's disease: initial outcome and long-term results. J Clin Endocrinol Metab 89: 6348–6357
Hofmann BM et al. (2008) Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. J Neurosurg 108: 9–18
Invitti C et al. (1999) Diagnosis and management of Cushing's syndrome: results of an Italian multicentre study. Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic–Pituitary–Adrenal Axis. J Clin Endocrinol Metab 84: 440–448
Knappe UJ and Lüdecke DK (1996) Persistent and recurrent hypercortisolism after transsphenoidal surgery for Cushing's disease. Acta Neurochir Suppl 65: 31–34
Rees DA et al. (2002) Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission. Clin Endocrinol (Oxf) 56: 541–551
Rollin GA et al. (2004) Dynamics of serum cortisol levels after transsphenoidal surgery in a cohort of patients with Cushing's disease. J Clin Endocrinol Metab 89: 1131–1139
Shimon I et al. (2002) Transsphenoidal surgery for Cushing's disease: endocrinological follow-up monitoring of 82 patients. Neurosurgery 51: 57–61
Yap LB et al. (2002) Undetectable postoperative cortisol does not always predict long-term remission in Cushing's disease: a single centre audit. Clin Endocrinol (Oxf) 56: 25–31
Ram Z et al. (1994) Early repeat surgery for persistent Cushing's disease. J Neurosurg 80: 37–45
Hofmann BM et al. (2006) Surgical treatment of recurrent Cushing's disease. Neurosurgery 58: 1108–1118
Friedman RB et al. (1989) Repeat transsphenoidal surgery for Cushing's disease. J Neurosurg 71: 520–527
Kim LJ et al. (2007) Preliminary experience with 3-Tesla MRI and Cushing's disease. Skull Base 17: 273–277
Friedman TC et al. (2007) Dynamic pituitary MRI has high sensitivity and specificity for the diagnosis of mild Cushing's syndrome and should be part of the initial workup. Horm Metab Res 39: 451–456
Watson JC et al. (1998) Localization of pituitary adenomas by using intraoperative ultrasound in patients with Cushing's disease and no demonstrable pituitary tumor on magnetic resonance imaging. J Neurosurg 89: 927–932
Catapano D et al. (2006) Comparison between the microscope and endoscope in the direct endonasal extended transsphenoidal approach: anatomical study. J Neurosurg 104: 419–425
Kitano M et al. (2008) Extended transsphenoidal approach for surgical management of pituitary adenomas invading the cavernous sinus. J Neurosurg 108: 26–36
Liu JK et al. (2003) Hypophysial transposition (hypophysopexy) for radiosurgical treatment of pituitary tumors involving the cavernous sinus. Technical note. Neurosurg Focus 14: e11
Kong DS et al. (2007) The efficacy of fractionated radiotherapy and stereotactic radiosurgery for pituitary adenomas: long-term results of 125 consecutive patients treated in a single institution. Cancer 110: 854–860
Castinetti F et al. (2007) Gamma knife radiosurgery is a successful adjunctive treatment in Cushing's disease. Eur J Endocrinol 156: 91–98
Jagannathan J et al. (2007) Gamma Knife surgery for Cushing's disease. J Neurosurg 106: 980–987
Feigl GC et al. (2002) Effects of gamma knife radiosurgery of pituitary adenomas on pituitary function. J Neurosurg 97: 415–421
Petit JH et al. (2008) Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocrinol Metab 93: 393–399
Engelhardt D and Weber MM (1994) Therapy of Cushing's syndrome with steroid biosynthesis inhibitors. J Steroid Biochem Mol Biol 49: 261–267
Castinetti F et al. (2008) Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. Eur J Endocrinol 158: 91–99
Gross BA et al. (2007) Medical management of Cushing disease. Neurosurg Focus 23: E10
O'Riordain DS et al. (1994) Long-term outcome of bilateral adrenalectomy in patients with Cushing's syndrome. Surgery 116: 1088–1093
Thompson SK et al. (2007) Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing's disease: a 10-year experience. Ann Surg 245: 790–794
Nelson DH et al. (1960) ACTH-producing pituitary tumors following adrenalectomy for Cushing's syndrome. Ann Intern Med 52: 560–569
Kemink SA et al. (1999) Progression of a Nelson's adenoma to pituitary carcinoma; a case report and review of the literature. J Endocrinol Invest 22: 70–75
Xing B et al. (2002) Microsurgical treatment of Nelson's syndrome. Chin Med J (Engl) 115: 1150–1152
Assié G et al. (2007) Corticotroph tumor progression after adrenalectomy in Cushing's disease: a reappraisal of Nelson's Syndrome. J Clin Endocrinol Metab 92: 172–179
Jenkins PJ et al. (1995) The long-term outcome after adrenalectomy and prophylactic pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 80: 165–171
Kelly PA et al. (2002) Neurosurgical treatment of Nelson's syndrome. J Clin Endocrinol Metab 87: 5465–5469
Kemink SA et al. (2001) Management of Nelson's syndrome: observations in fifteen patients. Clin Endocrinol (Oxf) 54: 45–52
Boscaro M . et al. (2006) Pasireotide (SOM230), the novel multi-ligand somatostatin analogue, is a promising medical therapy for patients with Cushing's disease: preliminary safety and efficacy results of a Phase II study. Presented at the 88th Endocrine Society Annual Meeting: 2006 June 24–27, Boston, MA
Giacomini D et al. (2006) Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. Endocrinology 147: 247–256
Castillo V et al. (2006) Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 147: 4438–4444
Lee EJ et al. (2001) Adenovirus-mediated targeted expression of toxic genes to adrenocorticotropin-producing pituitary tumors using the proopiomelanocortin promoter. J Clin Endocrinol Metab 86: 3400–3409
Kobayashi T et al. (2002) Gamma knife radiosurgery in the treatment of Cushing disease: long-term results. J Neurosurg 97: 422–428
Hoybye C et al. (2001) Adrenocorticotropic hormone-producing pituitary tumors: 12- to 22-year follow-up after treatment with stereotactic radiosurgery. Neurosurgery 49: 284–291
Izawa M et al. (2000) Gamma knife radiosurgery for pituitary adenomas. J Neurosurg 93 (Suppl 3): 19–22
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Aghi, M. Management of recurrent and refractory Cushing disease. Nat Rev Endocrinol 4, 560–568 (2008). https://doi.org/10.1038/ncpendmet0947
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpendmet0947
This article is cited by
-
Surgical and radiosurgical treatment strategies for Cushing’s disease
Journal of Neuro-Oncology (2019)
-
Approach to the postoperative patient with Cushing’s disease
Pituitary (2015)
-
Up-to 5-year efficacy of pasireotide in a patient with Cushing’s disease and pre-existing diabetes: literature review and clinical practice considerations
Pituitary (2015)
-
Downregulation of Insulin-like growth factor binding protein 6 is associated with ACTH-secreting pituitary adenoma growth
Pituitary (2014)
-
Pituitary tumors
Current Treatment Options in Neurology (2009)